Insmed (INSM) Competitors $159.10 +0.82 (+0.51%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. SNY, GSK, TAK, ARGX, ONC, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors Sanofi GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Insmed (NASDAQ:INSM) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Do insiders & institutionals have more ownership in INSM or SNY? 14.0% of Sanofi shares are held by institutional investors. 3.0% of Insmed shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, INSM or SNY? Sanofi has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M92.84-$913.77M-$5.71-27.98Sanofi$44.46B2.72$6.02B$4.1611.82 Do analysts rate INSM or SNY? Insmed currently has a consensus target price of $149.06, suggesting a potential downside of 6.69%. Sanofi has a consensus target price of $62.67, suggesting a potential upside of 27.44%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 1 Sell rating(s) 1 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86Sanofi 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility & risk, INSM or SNY? Insmed has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Does the media refer more to INSM or SNY? In the previous week, Sanofi had 1 more articles in the media than Insmed. MarketBeat recorded 23 mentions for Sanofi and 22 mentions for Insmed. Insmed's average media sentiment score of 0.67 beat Sanofi's score of 0.49 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 6 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Is INSM or SNY more profitable? Sanofi has a net margin of 21.47% compared to Insmed's net margin of -259.82%. Sanofi's return on equity of 16.86% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-259.82% -195.37% -49.49% Sanofi 21.47%16.86%9.63% SummarySanofi beats Insmed on 12 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.77B$3.31B$6.12B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-27.9821.5685.7226.88Price / Sales92.84412.90581.25184.02Price / CashN/A46.3226.3031.10Price / Book99.8410.0213.226.67Net Income-$913.77M-$52.22M$3.30B$276.44M7 Day Performance10.95%5.57%4.78%3.10%1 Month Performance10.10%11.80%8.42%10.19%1 Year Performance126.60%25.31%87.67%40.32% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.4185 of 5 stars$159.10+0.5%$149.06-6.3%+119.0%$33.63B$363.71M-27.861,271SNYSanofi4.2536 of 5 stars$45.65+0.2%$62.67+37.3%-10.4%$112.09B$44.46B10.9782,878High Trading VolumeGSKGSK2.1953 of 5 stars$41.08+3.1%$37.38-9.0%+11.9%$83.57B$40.10B19.0268,629Dividend CutTAKTakeda Pharmaceutical2.1384 of 5 stars$14.60-1.0%N/A+0.9%$46.44B$30.09B48.6547,455ARGXargenex3.7598 of 5 stars$719.04+1.0%$789.20+9.8%+48.7%$44.01B$2.25B36.871,599Positive NewsONCBeOne Medicines1.5401 of 5 stars$332.83+2.1%$336.30+1.0%N/A$36.48B$3.81B-192.3911,000Positive NewsBNTXBioNTech2.6528 of 5 stars$98.10+0.0%$134.56+37.2%-14.3%$23.58B$2.98B-61.316,772TEVATeva Pharmaceutical Industries3.0171 of 5 stars$19.17+4.5%$25.14+31.2%+14.3%$21.99B$16.54B-119.8136,830GMABGenmab A/S4.2491 of 5 stars$29.33+0.9%$40.00+36.4%+41.8%$18.82B$3.12B14.742,682High Trading VolumeSMMTSummit Therapeutics3.3317 of 5 stars$21.16+1.0%$31.29+47.9%+16.0%$15.72B$700K-20.95110ASNDAscendis Pharma A/S3.1514 of 5 stars$191.60-0.2%$244.36+27.5%+47.8%$11.81B$393.54M-37.131,017Positive News Related Companies and Tools Related Companies Sanofi Competitors GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
